Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120049) titled 'Treatment Strategy for patients with rheumatoid arthritis associated interstitial lung disease' on March 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking Union Medical College Hospital
Condition:
rheumatoid arthritis,interstitial lung disease
Intervention:
Standard therapy:Standard therapy
Tocilizumab treatment group:Tocilizumab
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-15
Target Sample Size: Standard therapy:68;Tocilizumab treatment group:68;Telitacicept treatment group:68;
Countries of Recruitment:
China
To know more, visi...